The team’s strategy began with forward genetics in the nematode Caenorhabditis elegans, a workhorse of developmental biology whose translucent body and well-mapped nervous system make it ideal for visualizing cellular defects. The researchers focused on two ciliary tubulins, TBA-5 and TBB-4, which are the worm counterparts of human tubulins implicated in ciliopathy. Worms carrying the tba-5(A19V) or tbb-4(L253F) mutations show defective sensory cilia, structures whose axonemal microtubules depend on precisely assembled tubulin. Ciliary failure can be scored conveniently through a dye-filling assay, because animals with broken cilia cannot take up fluorescent lipophilic dyes. Using ethyl methanesulfonate mutagenesis to sprinkle random point mutations across the genome, the team screened thousands of progeny for animals in which ciliary function re-emerged despite the presence of the toxic allele. This classic suppressor-screening logic—mutate at random, then ask which second-site changes rescue the phenotype—allowed the investigators to let evolution reveal the rules of tubulin suppression rather than guessing at them in advance.

The screen was remarkably productive, and its output fell into three functionally distinct classes of tubulin-autonomous missense suppressors. The most medically interesting category proved to be intergenic suppressors: missense variants arising not in the mutant gene itself but in the reciprocal partner tubulin. Because microtubules are obligate heteropolymers of α- and β-tubulin, a compensating change in the partner chain can, in principle, rebalance the assembly system. Two mechanistic subtypes emerged among these intergenic suppressors. The first, designated Sup I, consists of assembly-defective variants that rescue through competitive exclusion. These mutant partner tubulins bind the toxic tubulin in nonproductive heterodimers, sequestering it and preventing it from co-polymerizing into filaments, thereby protecting the pool of wild-type tubulin that remains free to assemble a normal microtubule network. Crucially, the team showed that this is a genuine gain-of-function effect: loss-of-function null alleles of the same gene could not achieve the rescue, and the suppressive variants specifically blocked incorporation of the pathogenic tubulin into microtubules in transfected cells.

The second and third classes, Sup II and Sup III, act through an entirely different principle. These are assembly-competent variants that themselves incorporate into microtubules alongside the diseased tubulin and modulate filament dynamics in a way that counteracts the mutation’s effect. Rather than removing the poison, they dilute and stabilize it from within, restoring the delicate balance of growth and shrinkage—dynamic instability—that healthy microtubules must maintain. The authors demonstrated these mechanisms in human cells, using HeLa cell lines engineered with split-GFP and epitope-tagged tubulin constructs to visualize how disease variants such as TUBA4A(E284G) and TUBB8(V229A) shatter the microtubule network, and how co-expressed suppressor variants from the reciprocal isotype family rebuild it. Pull-down assays with tagged constructs confirmed that both classes of suppressor form heterodimers with the pathogenic tubulins, yet their consequences for the polymer differ sharply: competitive exclusion in one case, dynamic rescue in the other.

Perhaps the most striking finding is the conservation of these mechanisms across evolutionary distance. Selected intergenic suppressors identified in worms were transplanted into human cells and rescued pathogenic tubulin-induced microtubule defects there as well. More ambitiously, the team moved into murine oocytes, where the β-tubulin isotype TUBB8 dominates the meiotic spindle and mutations in TUBB8 are a known cause of human oocyte maturation arrest and female infertility. In oocytes carrying tubulinopathy-related tubulin variants, the Sup III class of assembly-competent suppressors rescued meiotic spindle defects, outperforming supplementation with wild-type tubulin itself. This result carries a conceptual punch: simply adding more of the normal protein is not the best way to counter a dominant-negative poison, whereas a rationally chosen gain-of-function variant can outperform the wild type. It suggests that for dominant disorders, the therapeutic goal should not merely be replacement but active suppression tuned to the specific biophysical lesion caused by each patient mutation.

To understand how assembly-competent suppressors work at the molecular level, the researchers conducted a systematic mutational analysis of TUBA1A, the human α-tubulin most frequently implicated in cortical malformations. By mapping a landscape of variants capable of rescuing pathogenic β-tubulin mutants, they defined a cohort of gain-of-function, assembly-competent suppressors scattered across the tubulin sequence. Molecular dynamics simulations then illuminated the physical basis of the rescue. Microtubules are built from protofilaments—longitudinal strings of tubulin dimers that associate laterally to form the tube—and their geometry is exquisitely sensitive to the conformation of each subunit. Pathogenic mutations distort this geometry, bending protofilaments away from the correct lattice curvature and destabilizing the growing tip. The simulations showed that compensating suppressor mutations restore protofilament geometry, re-establishing the distances and contacts, including those near the GTP-binding pocket, that allow the lattice to close properly and dynamic instability to proceed normally.

The technical infrastructure behind the study is as noteworthy as its biological conclusions. The team employed AlphaFold-guided engineering of split-GFP technology to label endogenous tubulins without perturbing their function, allowing them to track incorporation of specific variants into cellular microtubule networks with high fidelity. Deep learning-based phenotypic classification accelerated the scoring of cellular rescue, and total internal reflection fluorescence microscopy captured in vitro microtubule dynamics in real time, showing directly that suppressor variants restore the growth and shrinkage behavior of individual filaments disrupted by pathogenic tubulins. Molecular dynamics trajectories, run for extended timescales on model protofilaments composed of TUBA1A and TUBB8, were deposited in public repositories alongside custom analysis code, reflecting a commitment to transparency that other labs can build upon.

The medical implications are considerable, though the authors are careful to frame the work as a foundation rather than a therapy. Tubulinopathies are genetically heterogeneous, with pathogenic variants across multiple α- and β-tubulin genes producing overlapping but distinct clinical spectra, and current management is largely supportive. A framework that maps which suppressor variants neutralize which pathogenic mutations—and defines the structural logic connecting sequence change to microtubule mechanics—opens a path toward what the authors describe as precision therapeutics for dominant tubulinopathies. In principle, allele-specific suppressors could be delivered through gene therapy vectors to neurons or other affected tissues, a strategy conceptually similar to suppressor-based approaches now being explored for other dominant-negative diseases such as certain dystrophies and neurodegenerative conditions. The demonstration that engineered suppressors outperform wild-type supplementation in oocytes is particularly encouraging for reproductive medicine, where TUBB8-related infertility currently offers few options.

There are, of course, substantial distances between a rescue in a HeLa cell or a mouse oocyte and a treatment for a child with lissencephaly. Delivery to the developing brain, dosage control, immune considerations and the risk that suppressor variants themselves perturb microtubule function in unanticipated ways all remain open questions, and the study’s own data show that different suppressor classes suit different mutational contexts. Yet the conceptual advance is unambiguous. By converting a devastating class of dominant mutations into an addressable engineering problem—and by showing that the solution generalizes from nematode cilia to human cells to mammalian oocytes—Xu, Guo and colleagues have transformed how the field can think about tubulinopathies. The humble suppressor screen, one of the oldest tools in genetics, has once again delivered insights that no amount of pure structural prediction could have supplied, and in doing so it has sketched the outline of a rational therapeutic playbook for disorders long considered untreatable at their molecular root.

Subject of Research: Gain-of-function tubulin suppressor variants that restore microtubule dynamics in dominant-negative tubulinopathies

Article Title: Gain-of-function suppressors restore microtubule dynamics and rescue dominant-negative tubulinopathies

Article References: Xu, K., Guo, Z., Ke, J., Chen, Z., Mao, L., Sun, R., Chen, M., Na, J., Xie, S., Zhou, T., Zhang, J., Wang, H., Shi, S.-H., Li, W., & Ou, G. (2026). Gain-of-function suppressors restore microtubule dynamics and rescue dominant-negative tubulinopathies. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02066-9

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02066-9

Keywords: tubulinopathies, microtubules, tubulin, TUBA1A, suppressor screen, Caenorhabditis elegans, dominant-negative mutation, gain-of-function, molecular dynamics simulation, cilia, genetic rescue, precision therapeutics

The article, led by Carsten Janke of Institut Curie and Université Paris-Saclay together with Anna Akhmanova of Utrecht University and an international consortium of sixteen colleagues from institutions spanning Europe and the United States, lays out a coordinated agenda for the microtubule field. Its authors span structural biology, biophysics, cell biology, neuroscience, parasitology and computational modelling, reflecting their central conviction that progress will come not from any single discipline but from a deliberate fusion of them. The paper is punctuated by the admission that some of the most basic questions remain unexplored, including how the properties and functions of microtubules are affected by the chemical marks known as tubulin post-translational modifications, by disease-related mutations in tubulin genes, or by variation in the microtubule lattice itself.

Microtubules are hollow tubes assembled from αβ-tubulin dimers that stack into protofilaments, typically thirteen of which align laterally to form the wall of the polymer. What makes these structures extraordinary is their behaviour: individual microtubules stochastically switch between phases of growth and rapid shrinkage, a phenomenon called dynamic instability, which was first described by Tim Mitchison and Marc Kirschner in 1984. A stabilizing cap of GTP-bound tubulin at the growing plus end controls this behaviour, and its loss triggers catastrophic depolymerization. Beyond pure polymerization, microtubules can self-repair by incorporating new tubulin along damaged stretches of lattice, a property revealed in studies showing that lattice defects actually induce self-renewal and protect the polymers from destruction by molecular motors. These discoveries have transformed the view of microtubules from static beams into dynamic, self-healing machines.

The Roadmap emphasizes that microtubule function is not determined by the polymer alone but by a dense layer of regulation encoded on the tubulin subunit itself. Enzymes of the tubulin tyrosine ligase-like family decorate the unstructured carboxy-terminal tails of tubulin with modifications such as tyrosination, detyrosination, acetylation, glutamylation and glycylation, creating what has become known as the tubulin code. Recent structural work has shown, for example, that enzymes involved in polyglutamylation recognize microtubules through a quadrivalent mechanism that links microtubule geometry to the generation of localized modification patterns, and that protofilament-specific nanopatterns of these marks tune the mechanics of beating cilia. The Roadmap argues that understanding how this chemical language is written, read and erased across cellular contexts is one of the field’s most pressing challenges, particularly because disruptions in the code are now firmly linked to neurodegeneration, ciliopathies and other disorders.

Nowhere is the clinical relevance more evident than in the nervous system. Neurons depend on microtubule tracks for the long-range transport of organelles, messenger RNAs and signalling endosomes along axons and dendrites, a process powered by kinesin and dynein motor proteins. Mutations in tubulin genes such as TUBA1A cause lissencephaly, a severe developmental brain malformation, by perturbing neuronal migration, and variants in a growing list of tubulin genes underlie a spectrum of neurodevelopmental disorders collectively known as tubulinopathies. Defective axonal transport is a shared hallmark of motor neuron diseases, and recent work has shown that excessive polyglutamylation of tubulin in the brain is sufficient to drive neurodegeneration by disrupting transport, while restoring the balance of these modifications can rescue affected neurons. The Roadmap positions a systems-level understanding of these processes as essential for translating molecular insight into therapies.

The heart and the immune system tell equally compelling stories. In beating cardiomyocytes, detyrosinated microtubules act as load-bearing elements that buckle under contraction and stiffen the cell, and suppressing this modification improves cardiac function in models of heart failure. In immune cells, microtubule networks orchestrate cell shape, migration and the directed release of lytic granules by natural killer cells, while platelets, whose tubulin repertoire is dominated by the β1-tubulin isotype, rely on precisely regulated microtubule assembly during their biogenesis; mutations in the TUBB1 gene cause congenital macrothrombocytopenia and thyroid dysgenesis. The Roadmap argues that these tissue-specific roles cannot be understood piecemeal and demand approaches that bridge the molecular properties of tubulin to the physiology of whole organs.

Technological innovation sits at the centre of the proposed strategy. Cryo-electron microscopy and cryo-electron tomography now reveal microtubules and their associated proteins at near-atomic and in situ resolution, while expansion microscopy and ultrastructure expansion microscopy allow researchers to visualize centrioles, cilia and mitotic spindles in whole cells and tissues with nanometre precision. In vitro reconstitution, a tradition stretching back to the pioneering work of Tim Mitchison and Marc Kirschner and continued in landmark experiments showing that purified microtubules and motors can self-organize into asters and vortices, remains indispensable for dissecting minimal systems. These experimental approaches are increasingly paired with computational and physical models that simulate spindle assembly, microtubule network organization and chromosome movement, and the Roadmap calls for tighter coupling between modelling and experiment, including the development of virtual cells powered by artificial intelligence.

Recombinant tubulin technology is highlighted as a particularly transformative advance. For decades, biochemists were limited to native tubulin purified from brain tissue, a mixture of isotypes and modifications that obscured cause and effect. The ability to produce functional human tubulin dimers in defined isotypes, with controlled post-translational modifications, has now enabled researchers to show directly that different isotypes confer distinct dynamic properties, that detyrosination tunes microtubule stability through selective recruitment of associated factors, and that systematic mutagenesis can map the functional landscape of disease-linked variants. Combined with deep mutational scanning and artificial-intelligence-driven phenotyping, the authors argue, these tools will allow the effects of every clinically observed tubulin mutation to be predicted and tested, a goal that seemed out of reach only a few years ago.

The Roadmap also looks beyond animal cells, drawing attention to the diversity of microtubule arrays across eukaryotes, from the cortical arrays that guide plant cell morphogenesis to the subpellicular arrays of trypanosomes and the specialized mitotic machinery of parasites. Comparative studies of parasites such as Plasmodium have revealed that adaptations in tubulin sequence generate distinct microtubule architectures, mechanics and drug susceptibilities, opening avenues for species-selective therapeutics. The authors contend that this evolutionary breadth is not a curiosity but a resource: organisms that build microtubules with unusual lattices, modifications or assembly mechanisms offer natural experiments that can illuminate principles hidden in familiar model systems.

Ultimately, the Roadmap is an invitation to think bigger. Its authors conclude that the microtubule cytoskeleton will continue to inspire scientists for decades precisely because so many fundamental questions remain open: how microtubule arrays are organized and diversified in different cell types, how the tubulin code is orchestrated across space and time, how mechanical forces reshape and stabilize microtubule lattices in living cells, and how all of this integrates into the physiology of tissues and organisms in health, ageing and disease. By bridging the atomic structure of the tubulin dimer with the behaviour of mitotic spindles, migrating neurons and beating hearts, the field aims to transform its fragmented molecular knowledge into a coherent systems-level picture, one that could reshape how disorders ranging from neurodegeneration and cancer to ciliopathies and heart failure are understood and treated.

The historical depth of the field is worth appreciating. Microtubules were first visualized in the late nineteenth and early twentieth centuries, but their protein building block was only identified in the late 1960s, when colchicine-binding assays led to the isolation of what was soon named tubulin, and amino-acid analysis of sperm flagella confirmed it as the universal subunit of the polymer. The discovery of dynamic instability two decades later established that these polymers are fundamentally nonequilibrium structures, a insight that continues to shape how spindle assembly and chromosome movement are understood today.

Equally important is the cast of regulatory proteins that act on microtubules. Microtubule-associated proteins such as tau can condense on the lattice in regulated phases, altering how motors and severing enzymes engage the polymer, while enzymes that cut microtubules generate new seeds and reshape networks. Proteins like doublecortin, which is mutated in human brain malformations, illustrate how even lattice geometry itself can be read selectively, recognizing only specific protofilament numbers. These layered interactions, spanning motors, maps, severing enzymes and modifying enzymes, form the mechanistic vocabulary that any systems-level account of the cytoskeleton will ultimately need to integrate.

Subject of Research: Systems-level integration of microtubule cytoskeleton structure, regulation and function in physiology and disease

Article Title: Towards a systems-level view of the microtubule cytoskeleton and its functions in physiology and disease

Article References: Janke, C., Akhmanova, A., Bartolini, F., Bodakuntla, S., Del Bene, F., Hamel, V., Mitchison, T. J., Müller-Reichert, T., Nédélec, F., Nogales, E., Pigino, G., Roll-Mecak, A., Schiavo, G., Surrey, T., & Lansky, Z. (2026). Towards a systems-level view of the microtubule cytoskeleton and its functions in physiology and disease. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-026-01011-w

Image Credits: AI Generated

DOI: 10.1038/s41580-026-01011-w

Keywords: microtubules, tubulin code, post-translational modifications, dynamic instability, axonal transport, tubulinopathies, ciliopathies, neurodegeneration, mitotic spindle, cryo-electron tomography, in vitro reconstitution, systems biology